Exemestane Schedules and Breast Tissue Drug Levels
Author Information
Author(s): Davide Serrano, Harriet Johansson, Bjørn-Erik Bertelsen, Sara Gandini, Gunnar Mellgren, Parijatham Thomas, Katherine Crew, Nagi Kumar, Debora Macis, Valentina Aristarco, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Mauro D'Amico, Tania Buttiron-Webber, Irene Maria Briata, Stefano Spinaci, Viviana Galimberti, Lana A. Vornik, Eduardo Vilar, Powel H. Brown, Brandy M. Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea DeCensi
Primary Institution: European Institute of Oncology IRCCS, Milan, Italy
Hypothesis
Can alternative schedules of exemestane effectively suppress estradiol levels in breast tissue for cancer prevention?
Conclusion
Exemestane taken once daily showed higher drug concentrations in nonmalignant breast tissue compared to other schedules, suggesting lower doses may be effective for cancer prevention.
Supporting Evidence
- Exemestane and its metabolite levels were significantly higher in nonmalignant tissue in the daily dosing group.
- Estradiol suppression was nearly complete in nonmalignant tissue across all dosing schedules.
- A dose-response trend for estradiol was observed in malignant tissue.
- Participants were treatment-compliant and well-balanced in age and BMI.
- The study was approved by multiple institutional review boards.
Takeaway
This study looked at how different schedules of a breast cancer drug called exemestane affect hormone levels in breast tissue. It found that taking the drug every day works better than taking it less often.
Methodology
This was a presurgical, 3-arm, double-blind, phase IIb trial involving postmenopausal women with ER-positive breast cancer, comparing different dosing schedules of exemestane.
Potential Biases
The study was not powered to assess the impact of racial or ethnic differences.
Limitations
The study lacked samples from all participants and baseline tissue estradiol data due to limited biopsy material.
Participant Demographics
Out of 180 participants, 155 were White non-Hispanic postmenopausal women with ER-positive breast cancer.
Statistical Information
P-Value
<.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website